KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

被引:41
作者
Frost, Nikolaj [1 ,2 ,3 ]
Kollmeier, Jens [4 ]
Vollbrecht, Claudia [1 ,2 ,5 ]
Grah, Christian [6 ]
Matthes, Burkhard [6 ]
Pultermann, Dennis [1 ,2 ,3 ]
von Laffert, Maximilian [1 ,2 ,5 ]
Lueders, Heike [7 ]
Olive, Elisabeth [7 ]
Raspe, Matthias [1 ,2 ,3 ]
Mairinger, Thomas [8 ]
Ochsenreither, Sebastian [1 ,2 ,9 ]
Blum, Torsten [4 ]
Hummel, Michael [1 ,2 ,5 ]
Suttorp, Norbert [1 ,2 ,3 ]
Witzenrath, Martin [1 ,2 ,3 ]
Grohe, Christian [7 ]
机构
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Humboldt Univ, Freie Univ Berlin, Berlin, Germany
[3] Berlin Inst Hlth, Dept Infect Dis & Pulm Med, Berlin, Germany
[4] Lungenklin Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany
[5] Berlin Inst Hlth, Dept Pathol, Berlin, Germany
[6] Gemeinschaftskrankenhaus Havelhohe, Dept Pneumonol, Berlin, Germany
[7] Klin Pneumol Evangel Lungenklin Berlin Buch, Berlin, Germany
[8] Helios Klinikum Emil von Behring, Dept Pathol, Berlin, Germany
[9] Berlin Inst Hlth, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany
关键词
Non-small cell lung cancer (NSCLC); checkpoint inhibitors; KRAS mutations; TP53; mutations; IMMUNE CHECKPOINT INHIBITORS; PREDICTIVE-VALUE; KRAS MUTATIONS; CANCER; ASSOCIATION; EXPRESSION; BLOCKADE; OUTCOMES; TP53;
D O I
10.21037/tlcr-20-958
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pembrolizumab is a standard of care as first line palliative therapy in PD-L1 overexpressing (>= 50%) non-small cell lung cancer (NSCLC). This study aimed at the identification of KRAS and TP53-defined mutational subgroups in the PD-L1 high population to distinguish long-term responders from those with limited benefit. Methods: In this retrospective, observational study, patients from 4 certified lung cancer centers in Berlin, Germany, having received pembrolizumab monotherapy as first line palliative treatment for lung adenocarcinoma (LuAD) from 2017 to 2018, with PD-L1 expression status and targeted NGS data available, were evaluated. Results: A total of 119 patients were included. Rates for KRAS, TP53 and combined mutations were 52.1%, 47.1% and 21.9%, respectively, with no association given between KRAS and TP53 mutations (P=0.24). By trend, PD-L1 expression was higher in KRAS-positive patients (75% vs. 65%, P=0.13). Objective response rate (ORR), median progression-free survival (PFS) and overall survival (OS) in the KRAS(G12C) group (n=32, 51.6%) were 63.3%, 19.8 months (mo.) and not estimable (NE), respectively. Results in KRAS(other) and wild type patients were similar and by far lower (42.7%, P=0.06; 6.2 mo., P<0.001; 23.4 mo., P=0.08). TP53 mutations alone had no impact on response and survival. However, KRAS(G12C)/TP53 co-mutations (n=12) defined a subset of long-term responders (ORR 100.0%, PFS 33.3 mo., OS NE). In contrast, patients with KRAS(other)/TP53 mutations showed a dismal prognosis (ORR 27.3%, P=0.002; PFS 3.9 mo., P=0.001, OS 9.7 mo., P=0.02). Conclusions: A comprehensive assessment of KRAS subtypes and TP53 mutations allows a highly relevant prognostic differentiation of patients with metastatic, PD-L1 high LuAD treated upfront with pembrolizumab.
引用
收藏
页码:737 / 752
页数:16
相关论文
共 46 条
  • [1] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Aguilar, E. J.
    Ricciuti, B.
    Gainor, J. F.
    Kehl, K. L.
    Kravets, S.
    Dahlberg, S.
    Nishino, M.
    Sholl, L. M.
    Adeni, A.
    Subegdjo, S.
    Khosrowjerdi, S.
    Peterson, R. M.
    Digumarthy, S.
    Liu, C.
    Sauter, J.
    Rizvi, H.
    Arbour, K. C.
    Carter, B. W.
    Heymach, J. V.
    Altan, M.
    Hellmann, M. D.
    Awad, M. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659
  • [2] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [3] Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
    Aredo, Jacqueline, V
    Padda, Sukhmani K.
    Kunder, Christian A.
    Han, Summer S.
    Neal, Joel W.
    Shrager, Joseph B.
    Wakelee, Heather A.
    [J]. LUNG CANCER, 2019, 133 : 144 - 150
  • [4] Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
    Assoun, Sandra
    Theou-Anton, Nathalie
    Nguenang, Marina
    Cazes, Aurelie
    Danel, Claire
    Abbar, Baptiste
    Pluvy, Johan
    Gounant, Valerie
    Khalil, Antoine
    Namour, Celin E.
    Brosseau, Solenn
    Zalcman, Gerard
    [J]. LUNG CANCER, 2019, 132 : 65 - 71
  • [5] Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer
    Bange, Erin
    Marmarelis, Melina E.
    Hwang, Wei-Ting
    Yang, Yu-Xiao
    Thompson, Jeffrey C.
    Rosenbaum, Jason
    Bauml, Joshua M.
    Ciunci, Christine
    Alley, Evan W.
    Cohen, Roger B.
    Langer, Corey J.
    Carpenter, Erica
    Aggarwal, Charu
    [J]. JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 11
  • [6] Implementing TMB measurement in clinical practice: considerations on assay requirements
    Buettner, Reinhard
    Longshore, John W.
    Lopez-Rios, Fernando
    Merkelbach-Bruse, Sabine
    Normanno, Nicola
    Rouleau, Etienne
    Penault-Llorca, Frederique
    [J]. ESMO OPEN, 2019, 4 (01)
  • [7] Canc Genome Atlas Res Network, 2012, NATURE, V491, P288, DOI 10.1038/nature11666
  • [8] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
    Canon, Jude
    Rex, Karen
    Saiki, Anne Y.
    Mohr, Christopher
    Cooke, Keegan
    Bagal, Dhanashri
    Gaida, Kevin
    Holt, Tyler
    Knutson, Charles G.
    Koppada, Neelima
    Lanman, Brian A.
    Werner, Jonathan
    Rapaport, Aaron S.
    San Miguel, Tisha
    Ortiz, Roberto
    Osgood, Tao
    Sun, Ji-Rong
    Zhu, Xiaochun
    McCarter, John D.
    Volak, Laurie P.
    Houk, Brett E.
    Fakih, Marwan G.
    O'Neil, Bert H.
    Price, Timothy J.
    Falchook, Gerald S.
    Desai, Jayesh
    Kuo, James
    Govindan, Ramaswamy
    Hong, David S.
    Ouyang, Wenjun
    Henary, Haby
    Arvedson, Tara
    Cee, Victor J.
    Lipford, J. Russell
    [J]. NATURE, 2019, 575 (7781) : 217 - +
  • [9] Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
    Cha, Yoon Jin
    Kim, Hye Ryun
    Lee, Chang Young
    Cho, Byoung Chul
    Shim, Hyo Sup
    [J]. LUNG CANCER, 2016, 97 : 73 - 80
  • [10] Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
    Coelho, Matthew A.
    Trecesson, Sophie de Carne
    Rana, Sareena
    Zecchin, Davide
    Moore, Christopher
    Molina-Arcas, Miriam
    East, Philip
    Spencer-Dene, Bradley
    Nye, Emma
    Barnouin, Karin
    Snijders, Ambrosius P.
    Lai, Wi S.
    Blackshear, Perry J.
    Downward, Julian
    [J]. IMMUNITY, 2017, 47 (06) : 1083 - +